Nasdaq · CIK 0001839970
BLSM BlossomHill Therapeutics, Inc.
Insider trading from SEC Form 4. Last filing Aug 12, 2026. Close $17.27 on Oct 12, 2026, +9% from the 52-week low and -36% from the high.
In brief
BlossomHill Therapeutics, Inc. (BLSM) has 11 SEC Form 4 filings on file from 10 insiders, the latest filed on Aug 12, 2026. In the last 90 days insiders made 6 open-market buys worth $25M and 0 open-market sells worth $0, net +$25M.
6 open-market trades have been scored at BLSM. The newest: Orbimed Advisors LLC (director) bought $10M of stock on Aug 10, 2026, filed Aug 12, 2026, scored 56 (moderate). 6 insiders bought within 14 days of each other around Aug 10, 2026.
Last 90 days
Price and insider trades, last year
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at BlossomHill Therapeutics, Inc., scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 56Moderate | Orbimed Advisors LLC director buy | $10M 625,000 shares | +30% | - | |
| 61Notable | Carl L Gordon director buy | $10M 625,000 shares | +30% | - | |
| 58Moderate | Bihua Chen director, owner buy | $5.0M 312,500 shares | +9% | - | |
| 48Moderate | John P. Schmid director buy | $96k 6,000 shares | - | - | |
| 45Moderate | Jason A Keyes Chief Financial Officer buy | $11k 700 shares | - | - | |
| 38Weak | Vincent Paul Liptak General Counsel buy | $75k 4,700 shares | +4% | - |
Transactions
Every row filed, 43 in all.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Aug 10, 2026 | Orbimed Advisors LLC director | CConversion Common Stockindirect: See footnotes | +1,039,996 | - | - | 1,039,996 | Aug 12, 2026 |
| Aug 10, 2026 | Carl L Gordon director | CConversion Common Stockindirect: See footnotes | +1,039,996 | - | - | 1,039,996 | Aug 12, 2026 |
| Aug 10, 2026 | Orbimed Advisors LLC director | CConversion Common Stockindirect: See footnotes | +1,049,283 | - | - | 2,089,279 | Aug 12, 2026 |
| Aug 10, 2026 | Carl L Gordon director | CConversion Common Stockindirect: See footnotes | +1,049,283 | - | - | 2,089,279 | Aug 12, 2026 |
| Aug 10, 2026 | Orbimed Advisors LLC director | POpen-market purchase Common Stockindirect: See footnotes | +625,000 | $16.00 | $10M | 2,714,279 | Aug 12, 2026 |
| Aug 10, 2026 | Carl L Gordon director | POpen-market purchase Common Stockindirect: See footnotes | +625,000 | $16.00 | $10M | 2,714,279 | Aug 12, 2026 |
| Aug 10, 2026 | Orbimed Advisors LLC director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,039,996 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | Carl L Gordon director | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,039,996 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | Orbimed Advisors LLC director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,049,283 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | Carl L Gordon director | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,049,283 | $0.00 | $0 | 0 | Aug 12, 2026 |
| Aug 10, 2026 | Sundeep Agrawal director | CConversion Common Stockindirect: By Brahma BlossomHill Partners, LLC | +578,524 | - | - | 578,524 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Common Stockindirect: By The Li and Cui Family Trust | +1,600,682 | - | - | 1,600,682 | Aug 10, 2026 |
| Aug 10, 2026 | Jason A Keyes Chief Financial Officer | POpen-market purchase Common Stock | +700 | $16.00 | $11k | 700 | Aug 10, 2026 |
| Aug 10, 2026 | John P. Schmid director | POpen-market purchase Common Stock | +6,000 | $16.00 | $96k | 6,000 | Aug 10, 2026 |
| Aug 7, 2026 | Vincent Paul Liptak General Counsel | POpen-market purchase Common Stock | +2,500 | $15.80 | $40k | 109,212 | Aug 10, 2026 |
| Aug 6, 2026 | Carl L Gordon director | AGrant or award Director Stock Option (Right to Buy)derivative | +23,904 | $0.00 | $0 | 23,904 | Aug 10, 2026 |
| Aug 10, 2026 | Bihua Chen director, owner | CConversion Common Stockindirect: See footnotes | +1,599,993 | - | - | 1,599,993 | Aug 10, 2026 |
| Aug 6, 2026 | Geoffrey Raymond Oxnard Chief Medical Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +61,783 | $0.00 | $0 | 61,783 | Aug 10, 2026 |
| Aug 6, 2026 | Sundeep Agrawal director | AGrant or award Director Stock Option (Right to Buy)derivative | +23,904 | $0.00 | $0 | 23,904 | Aug 10, 2026 |
| Aug 6, 2026 | Jason A Keyes Chief Financial Officer | AGrant or award Employee Stock Option (Right to Buy)derivative | +56,746 | $0.00 | $0 | 56,746 | Aug 10, 2026 |
| Aug 10, 2026 | Vincent Paul Liptak General Counsel | POpen-market purchase Common Stock | +2,200 | $16.00 | $35k | 111,412 | Aug 10, 2026 |
| Aug 10, 2026 | Bihua Chen director, owner | CConversion Common Stockindirect: See footnotes | +1,701,541 | - | - | 3,301,534 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By The Li and Cui Family Trust | +113,435 | - | - | 1,714,117 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 10, 2026 | Sundeep Agrawal director | CConversion Series B Preferred Stockderivativeindirect: By Brahma BlossomHill Partners, LLC | -578,524 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Bihua Chen director, owner | POpen-market purchase Common Stockindirect: See footnotes | +312,500 | $16.00 | $5.0M | 3,614,034 | Aug 10, 2026 |
| Aug 10, 2026 | Vincent Paul Liptak General Counsel | CConversion Common Stockindirect: By Walter T. Liptak Revocable Trust | +22,687 | - | - | 22,687 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Common Stockindirect: By RongShan, LLC | +124,779 | - | - | 124,779 | Aug 10, 2026 |
| Aug 6, 2026 | Bihua Chen director, owner | AGrant or award Director Stock Option (Right to Buy)derivative | +23,904 | $0.00 | $0 | 23,904 | Aug 10, 2026 |
| Aug 6, 2026 | Vincent Paul Liptak General Counsel | AGrant or award Employee Stock Option (Right to Buy)derivative | +46,561 | $0.00 | $0 | 46,561 | Aug 10, 2026 |
| Aug 10, 2026 | Bihua Chen director, owner | CConversion Series A Preferred Stockderivativeindirect: See footnotes | -1,599,993 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Vincent Paul Liptak General Counsel | CConversion Series B Preferred Stockderivativeindirect: By Walter T. Liptak Revocable Trust | -22,687 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Bihua Chen director, owner | CConversion Series B Preferred Stockderivativeindirect: See footnotes | -1,701,541 | - | - | 0 | Aug 10, 2026 |
| Aug 6, 2026 | Yishan Li Executive Chairman | AGrant or award Employee Stock Option (Right to Buy)derivative | +112,701 | $0.00 | $0 | 112,701 | Aug 10, 2026 |
| Aug 6, 2026 | Jingrong Jean Cui President and CEO | AGrant or award Employee Stock Option (Right to Buy)derivative | +676,205 | $0.00 | $0 | 676,205 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Series Angel Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -1,600,682 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Series B Preferred Stockderivativeindirect: By The Li and Cui Family Trust | -113,435 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Yishan Li Executive Chairman | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
| Aug 10, 2026 | Jingrong Jean Cui President and CEO | CConversion Series B Preferred Stockderivativeindirect: By RongShan, LLC | -124,779 | - | - | 0 | Aug 10, 2026 |
Insiders
Everyone who has filed a Form 4 here.
- Sundeep Agrawaldirector
- Bihua Chenowner, other, ceo, chair, officer, director
- Jingrong Jean CuiPresident and CEO
- Carl L Gordondirector, owner
- Jason A KeyesChief Financial Officer
- Yishan LiExecutive Chairman
- Vincent Paul LiptakGeneral Counsel
- Orbimed Advisors LLCdirector, owner
- Geoffrey Raymond OxnardChief Medical Officer
- John P. Schmiddirector, other
Questions about BLSM
Answered from the filings on this page, as of the latest one.
Are insiders buying BLSM?
As of Aug 12, 2026, SEC Form 4 filings show 6 open-market buys worth $25M by 6 insiders and 0 open-market sells worth $0 by 0 insiders at BlossomHill Therapeutics, Inc. in the last 90 days, net +$25M. Only purchases (code P) and sales (code S) count; grants, option exercises and tax withholding do not.
Who was the last insider to trade BLSM on the open market?
Orbimed Advisors LLC (director) bought $10M of BLSM on Aug 10, 2026 and filed the Form 4 on Aug 12, 2026. InsiderTell scored 56 (moderate), with 6 insiders on the same side within 14 days.
How many insiders file Form 4 at BlossomHill Therapeutics, Inc.?
10 people have filed a Form 4 at BlossomHill Therapeutics, Inc., among them Sundeep Agrawal (director), Bihua Chen (10% owner, CEO, chair and director), Jingrong Jean Cui (President and CEO). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.